For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- LDP’s Generic League Aiming to Finalize Proposal in April for Honebuto Policy
February 21, 2023
- Avigan Used Improperly for 429 Patients in Observational Study: MHLW
February 21, 2023
- AZ’s Evusheld Gets Label Update on Repeat Dosing
February 21, 2023
- MHLW to Launch Fact-Finding Study on COVID-19 Vaccine Reactions
February 20, 2023
- Lilly’s Ulcerative Colitis Med Up for MHLW Panel Review on March 3
February 20, 2023
- Chuikyo OKs Pricing Plan for Xocova Listing, 100 Billion Yen Threshold for Possible Re-Pricing
February 16, 2023
- Generic Approval Roster Includes at Least 3 AGs; Azilva, Revlimid, Maintate
February 16, 2023
- MHLW Approves First Generics for Azilva, Revlimid towards June Listing
February 16, 2023
- Expert Panel Agrees on Need for Generic Industry Shakeup, Company Criteria Floated
February 16, 2023
- 5-Year Mandatory Stable Supply Rule for Generics under Scrutiny: Expert Panel
February 16, 2023
- Darzquro to Escape CEA-Based Price Tweaks, Padcev Faces Cuts
February 16, 2023
- Pfizer’s Omicron-Tailored Jab for Ages 5-11 on PAFSC Agenda for Feb. 27
February 16, 2023
- PM Vows Collab with Pharma for Drug Discovery; Health Minister on Relyvrio
February 16, 2023
- Daiichi Sankyo’s Nasal Flu Vaccine Up for MHLW Panel Review on February 27
February 15, 2023
- Label Revisions Ordered for GLP-1 Agents to Add New Side Effect Risks
February 15, 2023
- Japan Should Create Drug Discovery Command Tower: Chugai Honorary Chair
February 14, 2023
- Trade Group Calls for Predictability around SaMD Reimbursement: LDP Gathering
February 14, 2023
- J-TEC’s Cell Sheet for Vitiligo Now in Line for Approval in Japan
February 14, 2023
- Japan Extends Paxlovid Shelf Life to 24 Months
February 13, 2023
- Japan Ends Supply of Moderna’s Original COVID Vaccine
February 13, 2023
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…